Poor
Needs Revision
Patient Risk:
Moderate
Summary
Multiple muscle-pain-related claims (e.g., specific incidence percentages, dosing/timing effects, and detailed mechanistic/management statements) are not supported by the provided FDA label excerpts and several are absent or only partially supported.
Category Scores
Accurate Statements
By inhibiting HMG-CoA reductase and cholesterol synthesis in the liver, Lipitor lowers LDL cholesterol.
Supported by 12.1 Mechanism of Action.
Lipitor can cause myopathy, characterized by muscle aches or weakness with CPK increases, and therapy should be discontinued if myopathy is diagnosed or suspected or if markedly elevated CPK levels occur.
Supported by 5.1 Skeletal Muscle.
Patients should be advised to report unexplained muscle pain, tenderness, or weakness promptly, and severe symptoms warrant contacting a doctor.
Supported by 17.1 Muscle Pain and 5.1 Skeletal Muscle (report promptly; discontinue if suspected).
Unsupported Statements
Lipitor (atorvastatin) is a statin medication.
Absent from the provided label excerpts supplied (12.1, 5.1, 6.1, 17.1).
By reducing cholesterol produced in the liver, Lipitor helps to increase high-density lipoprotein (HDL) cholesterol.
Only variable increases in HDL-C are described in 12.1; the claim implies a direct/consistent increase.
Muscle pain is a common side effect of Lipitor.
The provided excerpts do not support characterizing 'muscle pain' as 'common side effect' in that exact way; although myalgia/myopathy are discussed, the claim is not explicitly supported as 'common.'
Up to 30% of patients taking Lipitor experience muscle pain.
Specific quantitative incidence not supported; absent from the provided label excerpts.
24% of patients taking Lipitor reported muscle pain.
Specific quantitative incidence not supported; absent from the provided label excerpts.
The exact mechanism of muscle pain caused by Lipitor is still not fully understood.
Not supported or stated in the provided label excerpts.
It is thought that Lipitor-related muscle pain is related to the way the medication affects the body's muscle cells.
Not supported or stated in the provided label excerpts.
When Lipitor is taken, it can cause a buildup of creatine kinase in the muscles, leading to muscle pain and weakness.
Only partial support: label defines myopathy with CPK elevations and advises discontinuation, but does not explicitly state 'buildup of creatine kinase in the muscles leading to...' as phrased.
Taking Lipitor at night may help reduce the risk of muscle pain.
Not supported; absent from provided label excerpts.
If experiencing muscle pain while taking Lipitor, switching to a different statin medication or adjusting the dosage may be recommended.
Not supported; absent from provided label excerpts.
Muscle pain while taking Lipitor is usually mild and temporary.
Not supported; absent from provided label excerpts.
Contradictions
Important Omissions
Label-based safety guidance for muscle effects includes considering risk factors (e.g., history of renal impairment) and emphasizes increased risk with certain interacting drugs/conditions; none of these are addressed in the extracted claims.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Unsupported quantitative incidence and unlabelled risk-reduction/management statements (e.g., 'at night' effect, 'few days' break, 'usually mild and temporary') could mislead decision-making compared with the label’s more specific guidance (report promptly; discontinue if suspected; increased risk with certain drugs/conditions).
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Needs Revision
Primary Issue
Several high-impact claims about muscle pain incidence, mechanisms, and management/timing are absent or only partially supported by the provided FDA label excerpts.
Suggested Improvement
Remove or rephrase unsupported quantitative and timing claims; align muscle-pain discussion to label-supported elements: advise reporting unexplained pain/tenderness/weakness, consider CPK/myopathy criteria and discontinue if suspected/CPK markedly elevated, and reference increased risk with interacting drugs and periods of upward dosage titration.